The four variants with level B evidence were KRAS or MAP2K1 mutations found in patients with histiocytic neoplasms, for which MEK inhibitors such as cobimetinib or trametinib could be utilized. This evidence concerns the gene MAP2K7 and histiocytic neoplasm.